Inclusion Criteria:  Patient over 18 years of age Diagnosis of PCA made according to the criteria of Denning et al. Eur Respir J. 2016 Previously initiated or newly initiated azole antifungal therapy for chronic lung disease complicated by CPA. Informed patients who did not object to the use of their data.  Exclusion Criteria:  Pregnant woman Co-medication affecting the pharmacokinetics of antifungal agents:  Enzyme inducing therapy (rifampin, rifabutin, phenytoin, phenobarbital, efavirenz, nevirapine, etravirine, ritonavir in the case of voriconazole) Drugs that may inhibit the metabolism of antifungal drugs (ritonavir and cobicistat for itraconazole and isavuconazole)  Patients under guardianship/guardianship Patients without social security coverage